OncoCipherPATIENT
Educational & Guideline Reference Notice: Unranked FDA-label and national guideline option categories and recruiting clinical trials for discussion with a licensed oncologist. Protocol drug dosing and autonomous treatment prescriptions are excluded.

← All Supported Cancers

Breast Cancer — Options & Clinical Trial Reference

Biomarker-guided reference covering hormone receptor (ER/PR), HER2 / HER2-low IHC/ISH, BRCA1/2, PIK3CA, AKT1/PTEN, ESR1, and recruiting clinical trials.

Module v5.0.0 · Curated SHA-256: 94b1c2d347d08e05 · Trial Snapshot: 2026-11-16

Key Biomarkers & Decision Factors:
versionstatuspending_status_valuesbiomarkers

Unranked Guideline & FDA-Label Option Categories (64 total)

Option / PathwayCategoryPrimary Sources
Breast and axillary surgery planning
Multidisciplinary review of breast and axillary local treatment.
Local carenci
Postoperative radiation review
Review breast, chest wall and nodal radiation needs with the local team.
Local carenci
Adjuvant endocrine treatment
Confirm endocrine agent, menopausal physiology and ovarian suppression where appropriate.
Endocrine therapynci
Preoperative aromatase inhibitor review
Consider endocrine downstaging in a selected postmenopausal patient.
Endocrine therapynci
Early chemotherapy review
Choose a regimen after recurrence-risk, comorbidity and genomic-assay review where applicable.
Chemotherapynci
Abemaciclib plus adjuvant endocrine therapy
High-risk node-positive disease under the revised monarchE label.
Adjuvant targeted therapyabema, abema_label, verzenio_coverage_20261109
Ribociclib plus adjuvant aromatase inhibitor
Stage II or III high-risk disease after explicit NATALEE risk review.
Adjuvant targeted therapyribo_adj, ribo_label, kisqali_coverage_20261109
Adjuvant olaparib
Germline BRCA-associated high-risk disease after chemotherapy and definitive local care.
Adjuvant targeted therapyolaparib
T-DXd followed by taxane, trastuzumab and pertuzumab
Newly approved neoadjuvant sequence for HER2-positive stage II–III disease.
Neoadjuvant HER2 therapytdxd_early, enhertu
Trastuzumab, pertuzumab and chemotherapy before surgery
HER2-positive disease meeting tumor-size or nodal criteria.
Neoadjuvant HER2 therapyperjeta
Trastuzumab, pertuzumab and adjuvant chemotherapy review
Review a HER2-directed adjuvant course for high-risk disease.
Adjuvant HER2 therapyperjeta
T-DXd after residual invasive HER2-positive disease
Adjuvant T-DXd after trastuzumab and taxane-based neoadjuvant treatment.
Post-neoadjuvant HER2 therapytdxd_early, enhertu
Pembrolizumab with chemotherapy, then postoperative pembrolizumab
Review the complete KEYNOTE-522 perioperative course.
Perioperative TNBC therapykn522_label, kn522, kn522_os
Complete planned postoperative pembrolizumab
Continuation of an established perioperative regimen after surgery.
Post-neoadjuvant TNBC therapykn522_label
Adjuvant capecitabine for residual TNBC
Evidence-supported off-label review after residual disease following chemotherapy.
Post-neoadjuvant chemotherapycreatex, dpyd

View all 64 Breast Cancer reference options →

Recruiting Clinical Trials (43 curated)

NCT IDStudy TitlePhase
NCT01042379I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)PHASE2
NCT03606967Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab + Neoantigen Vaccine vs. Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab in Patients With Metastatic Triple Negative Breast CancerPHASE2
NCT03936478A Phase II Study of Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer (MAPBI)PHASE2
NCT03990896Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical TrialPHASE2
NCT04084730Ultra-Short External Beam-Based Accelerated Partial Breast Irradiation (APBI): A Phase II Toxicity Study Nested With a Non-inferiority Assessment of APBI in New Patient CohortsPHASE2
NCT04722692Sentinel Lymph Node Biopsy in Ductal Cancer in Situ or Unclear Lesions of the Breast and How to Not do it. An Open-label, Phase 3, Randomised Controlled Trial. (SentiNot 2.0).PHASE3
NCT04768426Phase II Trial of Circulating Tumor DNA Monitoring During Adjuvant Capecitabine in Patients With Triple-negative Breast Cancer and Residual Disease Following Standard Neoadjuvant ChemotherapyPHASE2
NCT04787042A First-In-Human Phase 1/2 Open-Label Study of Intravenous ST-067, Subcutaneous ST-067 with or Without Obinutuzumab Pre-Treatment, and ST-067 in Combination with Pembrolizumab in Subjects with Advanced Solid MalignanciesPHASE1/PHASE2
NCT04802759A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS-BREAST CANCER)PHASE1/PHASE2
NCT04899908A Double-blind, Phase II Randomized Study of Brain-directed Stereotactic Radiation With or Without AGuIX Gadolinium-based Nanoparticles in the Management of Brain Metastases at Higher Risk of Local Recurrence With Radiation AlonePHASE2
NCT05013255Pioglitazone Therapy Targeting Fatigue in Breast CancerPHASE2
NCT05232916A Randomized, Multicenter, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects With Residual Disease or High-Risk PCR After Both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01)PHASE3

View all 43 Breast Cancer clinical trials →